Orthobiologics Devices and Equipment Global Market Report 2024

The orthobiologics devices and equipment market size has grown strongly in recent years. It will grow from $5.29 billion in 2023 to $5.74 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth observed in the historical period can be attributed to the introduction of innovative devices to the market, increased focus on clinical research and trials, a surge in sports-related injuries and the aging population, adherence to regulatory standards, and the evolution of implant designs.

The orthobiologics devices and equipment market size is expected to see strong growth in the next few years. It will grow to $7.39 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The anticipated growth in the forecast period can be credited to AI-assisted surgical planning, initiatives promoting value-based healthcare, expanding markets in emerging economies, the development of precision surgery tools, and an increased emphasis on regenerative medicine. Noteworthy trends expected in the forecast period encompass AI-assisted planning and simulation, the provision of patient-specific solutions, improved integration of biologics, the promotion of minimally invasive procedures, and a heightened focus on regenerative therapies.

The global growth of the orthobiologics devices and equipment market has been influenced by the aging population profiles in most countries. As per a United Nations report, the global population included 962 million individuals aged over 60, constituting 13% of the total population. This age group is anticipated to experience an annual growth rate of around 3%. Europe was identified as having the highest percentage of the population aged over 60. The global count of individuals over 65 increased by 33%, based on estimates derived from Population Reference Bureau data. The rise in the aging population has expanded the patient pool for various orthopedic disorders, fostering an increased demand for orthobiologics devices and equipment.

The anticipated growth of the orthobiologics devices and equipment market is further driven by the increasing prevalence of arthritis. Arthritis encompasses over 100 inflammatory joint diseases affecting the musculoskeletal system. Orthobiologics devices and equipment play a crucial role in improving arthritis management by reducing pain, enhancing joint function, and providing minimally invasive, personalized, and more natural treatment options. According to a report in February 2022, the number of people with arthritis is expected to rise by 67 million by 2030. This surge in arthritis cases is a significant factor propelling the growth of the orthobiologics devices and equipment market.

A notable restraint in the orthobiologics devices and equipment market is the rising incidence of post-surgical complications in patients who have undergone orthobiologics procedures. Surgical interventions involving orthobiologics grafts, implants, and devices have become increasingly prevalent, leading to potential complications such as device failures, bleeding, postoperative infections, immune responses, and rejections. These complications can vary based on factors such as the type of procedure, implant or device used, the surgeon's experience, inadequate testing procedures before market launch, device location in the body, and the individual's health and biological response. The growing occurrence of post-operative complications and device failures poses a limitation to the orthobiologics devices and equipment market.

The utilization of biodegradable implants is becoming increasingly prevalent in orthobiologics treatment and trauma orthopedic surgeries. These implants serve the purpose of replacing a missing biological structure, supporting a damaged one, and enhancing existing bone structures. Biodegradable products, such as re-absorbable polymers made from polyglycolic acid and polylactic acid in the form of plates, screws, and pins, are gradually replacing more expensive traditional devices such as plates and screws. Surgeons are favoring biodegradable implants over conventional ones because they can be engineered to provide temporary support for bone fractures, degrade at a rate aligned with new tissue formation, eliminate the need for a second surgery, and are particularly useful in fracture fixation for children, reducing the risk of implant-related infections. For example, Stryker Corp. offers orthobiologics, including bone repair biodegradable products used in bone regeneration, healing, soft tissue regeneration, and muscle connection to bone.

Major companies in the orthobiologics devices and equipment market are emphasizing innovative products, such as the NorthStar facet fusion, to boost revenues. The NorthStar facet fusion system is designed to offer stability and support for targeted facet joints, alleviating pain and symptoms associated with conditions such as facet joint arthritis, degenerative disc disease, and other spinal disorders. Seaspine Holdings Corporation, a US-based medical device company, launched the NorthStar facet fusion in March 2022, combining Osteostrand DBM fiber cervical pellets with disposable facet preparation tools. This fusion system is intended for use with the NorthStar OCT posterior cervical fixation system.

Anticipated regulatory changes may result in increased costs for new product development and the supply of orthobiologics devices. These changes include measures related to customer data protection, such as the European Union's General Data Protection Regulation (GDPR), adjustments to equipment approval procedures, and other regulatory modifications. The GDPR, governing data protection and privacy for individuals in the EU and EEA, also regulates the export of personal data outside these regions. Additionally, the FDA is demanding more clinical data to support claims, leading to an over 55% increase in processing time for 510(k)s over the last decade. Potential stricter regulations for the development and approval of orthobiologics devices may result in increased costs for clinical trials, data collection, and compliance. Delays in product release, additional expenses due to prolonged approval processes, and changing regulations pose challenges to investments in the development of orthobiologics devices.

Major companies operating in the orthobiologics devices and equipment market report are BONESUPPORT AB, Sanofi SA, Medtronic plc, Kuros Biosciences Ltd., Stryker Corporation, Baxter International Inc., DePuy Synthes, Braun Melsungen AG, Zimmer Biomet Holdings Inc., Terumo BCT Inc., Terumo Corporation, Smith & Nephew plc, Arthrex Inc., Enovis Corp., Integra Lifesciences Holding Corporation, NuVasive Inc., Globus Medical Inc., Wright Medical Group NV, Bioventus LLC, Orthofix Medical Inc., Pioneer Surgical Technology Inc., RTI Surgical Inc., SeaSpine Holdings Corporation, Xtant Medical Holdings Inc., Acumed LLC, Bone Biologics Corp., Osiris Therapeutics Inc., K2M Group Holdings Inc., BSN medical Pvt. Ltd. North America was the largest region in the global Ortho biologics devices and equipment market in 2023. Western Europe was the second-largest region in the orthobiologics devices and equipment market report. The regions covered in the orthobiologics devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The primary product types within the realm of Ortho biologics devices and equipment encompass demineralized bone matrix, synthetic bone substitutes, stem cell therapy, plasma-rich protein, viscosupplementation, bone morphogenetic protein, and synthetic orthobiologics. Stem cell therapy plays a crucial role in enhancing the repair response of tissues affected by diseases, dysfunction, or injuries, utilizing stem cells or their derivatives. These ortho biologic applications find utility in addressing conditions such as osteoarthritis and degenerative arthritis, soft-tissue injuries, fracture recovery, maxillofacial and dental applications, spinal fusion, trauma repair, and reconstructive surgery. These devices are employed by various end-users, including hospitals, orthopedic clinics, and others.

The orthobiologics devices and equipment market research report is one of a series of new reports that provides orthobiologics devices and equipment market statistics, including orthobiologics devices and equipment industry global market size, regional shares, competitors with a orthobiologics devices and equipment market share, detailed orthobiologics devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the orthobiologics devices and equipment industry. This orthobiologics devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The countries covered in the orthobiologics devices and equipment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The orthobiologics devices and equipment market consists of sales of demineralized bone matrix, synthetic bone substitutes, stem cell therapy, plasma-rich protein, viscosupplementation, bone morphogenetic protein, and other synthetic orthobiologics. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.